• Biodesix to Present at 2011 Biotech Showcase

    January 7, 2011 Biodesix, Inc. announces that Paul Beresford, Ph.D., Vice President, Business Development and Strategic Marketing will present at the 2011 Biotech Showcase conference taking place January 10-12th at the Parc 55 Wyndham in San Francisco, California. Biodesix’ presentation will occur on Monday, January 10th, at 2:15 p.m. ... Read more
  • VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy

    November 19, 2010 Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany ... Read more
  • Biodesix Completes Series C Financing and Receives Grant

    November 5, 2010 Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors. The Series C round, which included 5 new investors, will support ongoing commercialization activities for the company’s first product VeriStrat®, a serum proteomic test that helps physicians guide treatment for patients with non-small cell lung cancer ... Read more
  • Biodesix Selected as a Colorado Company to Watch

    June 23, 2010 Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award.  Colorado Companies to Watch is a dynamic business recognition program honoring second-stage companies headquartered in the state of Colorado that are developing valuable products and services, creating quality jobs, enriching communities, and ... Read more
  • Biodesix Announces Issuance of Key Patent for Serum Test that Identifies Lung Cancer Patients Likely to Benefit from Targeted Therapy

    June 21, 2010 Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905.  The patent provides coverage for the Company’s first product, VeriStrat®, which is used by physicians to help guide therapy for patients ... Read more
  • New Data from Phase III Lung Cancer Trial Show VeriStrat® Identifies Patients Likely to Respond to Erlotinib

    May 6, 2010 Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed ... Read more
  • VeriStrat® Outcomes Data in Lung Cancer to be Presented at IASLC/ESMO 2nd European Lung Cancer Conference

    April 19, 2010 Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone, M.D., Ph.D., Professor of Medicine and Cancer Biology, Vanderbilt University School of Medicine, on Friday, April 30th at the 2nd European Lung Cancer Conference ... Read more
  • Biodesix CEO to Present at Personalized Medicine Partnerships Conference

    February 5, 2010 Biodesix, Inc. announces that David Brunel, Chief Executive Officer, will present at the 2010 Personalized Medicine Partnerships Conference, Wednesday, February 24th, at 11:00 a.m. eastern time. The conference takes place February 22-24th at the Doubletree Hotel in Philadelphia, PA, and will include presentations by both diagnostic ... Read more
  • Biodesix Secures $10 Million in Series B-1 Funding

    September 28, 2009 Funding to further the commercialization of VeriStrat® Biodesix, Inc., a privately held molecular diagnostics company focused on proteomic-based diagnostics discovery and commercialization, announced today that it has completed the initial tranche of its $10 million Series B-1 financing round. The financing was led by existing shareholders and ... Read more
  • Biodesix Announces VeriStrat® Data in Head and Neck Cancer to be Presented at ASCO

    May 14, 2009 Data support proteomic test as a predictor of overall survival benefit with EGFRI treatment Data on VeriStrat, a blood-based, proteomic test currently used for patients with advanced stage non-small-cell lung cancer (NSCLC), will be presented by Christine Chung, MD, Assistant Professor of Medicine at Vanderbilt University on ... Read more